Metabolomics: A New Era in the Diagnosis or Prognosis of B-Cell Non-Hodgkin's Lymphoma

被引:12
|
作者
Alfaifi, Abdullah [1 ,2 ]
Refai, Mohammed Y. [3 ]
Alsaadi, Mohammed [1 ,4 ]
Bahashwan, Salem [4 ,5 ,6 ]
Malhan, Hafiz [7 ]
Al-Kahiry, Waiel [7 ]
Dammag, Enas [7 ]
Ageel, Ageel [7 ]
Mahzary, Amjed [8 ]
Albiheyri, Raed [1 ]
Almehdar, Hussein [1 ]
Qadri, Ishtiaq [1 ]
机构
[1] King Abdulaziz Univ, Fac Sci, Dept Biol Sci, Jeddah 21589, Saudi Arabia
[2] Minist Hlth, Fayfa Gen Hosp, Jazan 83581, Saudi Arabia
[3] Univ Jeddah, Coll Sci, Dept Biochem, Jeddah 21493, Saudi Arabia
[4] King Abdulaziz Univ, King Fahad Med Res Ctr, Hematol Res Unit, Jeddah 21589, Saudi Arabia
[5] King Abdulaziz Univ, Fac Med, Dept Hematol, Jeddah 21589, Saudi Arabia
[6] King Abdulaziz Univ, King Abdulaziz Univ Hosp, Jeddah 21589, Saudi Arabia
[7] Minist Hlth, Prince Mohammed Bin Nasser Hosp, Jazan 82943, Saudi Arabia
[8] Minist Hlth, Eradah Hosp, Jazan 82943, Saudi Arabia
关键词
metabolomics; B-cell non-Hodgkin's lymphoma; biomarkers; metabolites; early diagnosis; therapeutic; GENOMIC URACIL; LARGE-SCALE; METABOLISM; SERUM; INHIBITION; MUTATIONS; EXPRESSION; LEUKEMIA; SURVIVAL; CHROMATOGRAPHY;
D O I
10.3390/diagnostics13050861
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A wide range of histological as well as clinical properties are exhibited by B-cell non-Hodgkin's lymphomas. These properties could make the diagnostics process complicated. The diagnosis of lymphomas at an initial stage is essential because early remedial actions taken against destructive subtypes are commonly deliberated as successful and restorative. Therefore, better protective action is needed to improve the condition of those patients who are extensively affected by cancer when diagnosed for the first time. The development of new and efficient methods for early detection of cancer has become crucial nowadays. Biomarkers are urgently needed for diagnosing B-cell non-Hodgkin's lymphoma and assessing the severity of the disease and its prognosis. New possibilities are now open for diagnosing cancer with the help of metabolomics. The study of all the metabolites synthesised in the human body is called "metabolomics." A patient's phenotype is directly linked with metabolomics, which can help in providing some clinically beneficial biomarkers and is applied in the diagnostics of B-cell non-Hodgkin's lymphoma. In cancer research, it can analyse the cancerous metabolome to identify the metabolic biomarkers. This review provides an understanding of B-cell non-Hodgkin's lymphoma metabolism and its applications in medical diagnostics. A description of the workflow based on metabolomics is also provided, along with the benefits and drawbacks of various techniques. The use of predictive metabolic biomarkers for the diagnosis and prognosis of B-cell non-Hodgkin's lymphoma is also explored. Thus, we can say that abnormalities related to metabolic processes can occur in a vast range of B-cell non-Hodgkin's lymphomas. The metabolic biomarkers could only be discovered and identified as innovative therapeutic objects if we explored and researched them. In the near future, the innovations involving metabolomics could prove fruitful for predicting outcomes and bringing out novel remedial approaches.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] The molecular pathogenesis of B-cell non-Hodgkin lymphoma
    Blombery, Piers A.
    Wall, Meaghan
    Seymour, John F.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 280 - 293
  • [42] Breakthrough therapies in B-cell non-Hodgkin lymphoma
    Cheah, C. Y.
    Fowler, N. H.
    Wang, M. L.
    ANNALS OF ONCOLOGY, 2016, 27 (05) : 778 - 787
  • [43] Identification of putative biomarkers for leptomeningeal invasion in B-cell non-Hodgkin lymphoma by NMR metabolomics
    Gonçalo Graça
    Joana Desterro
    Joana Sousa
    Carlos Fonseca
    Margarida Silveira
    Jacinta Serpa
    Tânia Carvalho
    Maria G. da Silva
    Luís G. Gonçalves
    Metabolomics, 2017, 13
  • [44] Identification of putative biomarkers for leptomeningeal invasion in B-cell non-Hodgkin lymphoma by NMR metabolomics
    Graca, Goncalo
    Desterro, Joana
    Sousa, Joana
    Fonseca, Carlos
    Silveira, Margarida
    Serpa, Jacinta
    Carvalho, Tania
    da Silva, Maria G.
    Goncalves, Luis G.
    METABOLOMICS, 2017, 13 (11)
  • [45] T-cell-rich B-cell non-Hodgkin's lymphoma mimicking Hodgkin's disease
    Bättig, B
    Mueller-Garamvoelgyi, E
    Cogliatti, SB
    Schmid, U
    Kappeler, A
    Cerny, T
    Laissue, JA
    Fey, MF
    LEUKEMIA & LYMPHOMA, 1999, 33 (3-4) : 393 - 398
  • [46] Simultaneous Diagnosis of Active Pulmonary Tuberculosis and B-Cell Non-Hodgkin's Lymphoma with Pleural Involvement
    Katzman, D. P.
    Sloane, M. F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [47] Antibody therapy for non-Hodgkin's B-cell lymphoma proves itself
    Clark, M
    LANCET, 1997, 349 (9044): : 34 - 34
  • [48] Radioimmunotherapy: A novel treatment modality for B-cell non-Hodgkin's lymphoma
    Juweid, M
    DeNardo, GL
    Graham, M
    Vose, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (05) : 673 - 674
  • [49] Proliferation and apoptosis in primary gastric B-cell non-Hodgkin's lymphoma
    Gisbertz, IAM
    Schouten, HC
    Bot, FJ
    Arends, JW
    HISTOPATHOLOGY, 1997, 30 (02) : 152 - 159
  • [50] Constitutive chemokine receptor expression in B-cell non-Hodgkin's lymphoma
    Bryson, Michelle S.
    Jarrett, Ruth F.
    Sheild, Lesley
    Graham, Gerard J.
    BLOOD, 2007, 110 (11) : 1050A - 1050A